The application of FRAX in Saudi Arabia.

Autor: Al-Daghri NM; Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia. ndaghri@ksu.edu.sa., Sabico S; Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia., Al-Saleh Y; Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City, Riyadh, Ministry of National Guard-Health Affairs, Riyadh, Kingdom of Saudi Arabia., Sulimani R; Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia., Aljohani NJ; Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia.; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia., Sheshah E; Diabetes Care Center, King Salman Bin Abdulaziz Hospital, Riyadh, Kingdom of Saudi Arabia., Alodhayani A; Department of Family Medicine and Community, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia., Harvey NC; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK., Liu E; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia., Lorentzon M; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.; Sahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden., McCloskey EV; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.; MRC and Arthritis Research UK Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK., Vandenput L; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Johansson H; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.; Sahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK., Kanis JA; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. w.j.pontefract@shef.ac.uk.; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.pontefract@shef.ac.uk.
Jazyk: angličtina
Zdroj: Archives of osteoporosis [Arch Osteoporos] 2021 Nov 05; Vol. 16 (1), pp. 166. Date of Electronic Publication: 2021 Nov 05.
DOI: 10.1007/s11657-021-01024-2
Abstrakt: Assessment and treatment pathways based on age-specific intervention thresholds in Saudi Arabi can be used to identify patients at high risk of fracture and avoid unnecessary treatment in those at low fracture risk.
Purpose: Intervention thresholds for the treatment of osteoporosis have historically been based on the measurement of bone mineral density. The aim of the present study was to explore treatment paths and characteristics of women eligible for treatment in Saudi Arabia based on fracture probabilities derived from FRAX®.
Methods: The approach to the setting of intervention and assessment thresholds used the methodology adopted by the National Osteoporosis Guideline Group for FRAX-based guidelines in the UK but based on the epidemiology of fracture and death in Saudi Arabia. The methodology was applied to women age 40 years or more drawn from a tertiary referral population for skeletal assessment. Missing data for the calculation of FRAX was simulated using data from the referral and FRAX derivation cohorts.
Results: Intervention thresholds expressed as a 10-year probability of a major osteoporotic fracture ranged from 2.0% at the age of 50 years increasing to 7.6% at the age of 70 years. A total of 163 of 1365 women (11.9%) had a prior fragility fracture and would be eligible for treatment for this reason. An additional 5 women were eligible for treatment in that MOF probabilities lay above the upper assessment threshold. A BMD test would be recommended for 593 women (43.4%) so that FRAX could be recalculated with the inclusion of femoral neck BMD. Of these, 220 individuals would be eligible for treatment after a BMD test and 373 women categorised at low risk after a BMD test.
Conclusion: Probability-based assessment of fracture risk using age-specific intervention thresholds was developed for Saudi Arabia to help guide decisions about treatment.
(© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.)
Databáze: MEDLINE
Externí odkaz: